Day: March 7, 2024

MONTEVIDEO, Uruguay, March 07, 2024 (GLOBE NEWSWIRE) — DLocal Limited (NASDAQ: DLO, “dLocal” or the “Company”), a technology-first payments platform enabling global enterprise merchants to connect with billions of consumers in emerging markets, intends to release financial results for its fourth fiscal quarter ended December 31, 2023 on March 18, 2024 after market close. The Company will host a conference call and video webcast on March 19, 2024 at 8:30 a.m. Eastern Time. Please click here to pre-register for the conference call and obtain your dial in number and passcode. The live conference call can be also accessed via audio webcast at the investor relations section of the Company’s website, at https://investor.dlocal.com/. An archive of the webcast will be available for one year following the conclusion of the conference call. About...

Company maintains solid cash position of $158.9 million SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2023. “We are working diligently to lift the clinical hold on our Phase 2 trials of zelnecirnon in atopic dermatitis and asthma,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “Patient safety is our top priority. We expect to provide an update once we have defined a plan to move ahead and appreciate your patience during this process. Separately,...

Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in a patient derived pancreatic cancer model No clinical and histopathologic signs of toxicities in non-human primates with conditionally active tetravalent B7-H3 x CD3 T-cell engager (BA3142)SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting...

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) — Elys BMG Group, Inc. (“Elys” or the “Company”) (OTC: ELYS), an interactive gaming and sports betting technology company, today announces that Grand Central Sportsbook in Washington D.C. (“Grand Central”) has been granted provisional approval to open its H Street sportsbook by the DC Office of Lottery and Gaming, Regulation and Oversight Division. As previously announced, this represents the third independently owned sportsbook venue in Washington, D.C. powered by Elys’ Gameboard betting technology. The grand opening of Grand Central H Street, located at 625-D H Street NE in Washington, D.C., is expected to take place ahead of the 2024 March Madness tournament and which will be announced along with planned promotions and events within the coming days. The Company is preparing to sequentially...

MURRAY, Utah, March 07, 2024 (GLOBE NEWSWIRE) — FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), parent company of FinWise Bank (the “Bank”), today announced that its Board of Directors has authorized a common stock repurchase program to purchase up to 641,832 shares, or approximately 5% of issued and outstanding shares, as of March 6, 2024. The repurchases will be made at the Company’s discretion through March 31, 2026. “As the Company remains well capitalized and continues to generate solid profitability, we are pleased that the Board of Directors has approved a new Share Repurchase Program,” said Kent Landvatter, Chief Executive Officer of FinWise. “Our differentiated business model and strong liquidity position allow us to return capital to shareholders via share buybacks while continuing to invest to become an...

Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high throughput optical genome mapping (OGM) and findings from early access customers The pre-conference event will also include a 2024 corporate overview from Bionano’s chief executive officer, Dr. Erik Holmlin, presentations from Dr. Brynn Levy at Columbia University Medical Center, Dr. Ulrich Broeckel at Medical College of Wisconsin, Dr. Susan Crocker at Kingston Health Sciences Centre, Dr. Liz McCready at Hamilton Health Science Center, and Dr. Zeid Hamadeh at Vancouver General Hospital covering the utility of OGM and VIA™ software and the adoption, implementation, and advanced research capabilities of the Stratys system, and will conclude with a fireside chat with panelists hosted by Bionano’s...

The application follows the Company’s approval from the New Mexico Board of Pharmacy this year. GRANTS, NM, March 07, 2024 (GLOBE NEWSWIRE) — Bright Green Corporation, a Delaware corporation (the “Company”), announced today the submission of its DEA Registration for Bulk Production of Schedule I and Schedule II Controlled Substances. The application is an official and substantial step in Bright Green’s expansion into the legal manufacturing of plant-based controlled substances including psilocybin, peyote, ibogaine, coca leaves, and opium poppy, alongside their active pharmaceutical ingredients (“API”) for medical, research, and other legal purposes. The move aligns with Bright Green’s commitment to providing a domestic supply of essential medications, addressing critical concerns associated with disruptions...

SINGAPORE, March 07, 2024 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announced today the launch of artificial intelligence (“AI”) Avatar C-Suite Teams on its Edtech platform, GeniusU, with the integration of 50 AI-powered “Expert” Avatars and Tools to support entrepreneurs. Following the successful launch of Genius Group’s AI Avatar Tutor Team, “Student AI”, which has attracted over 30,000 students within the first three months since launch, Genius Group has launched “Genius Team AI” for the 5.4 million entrepreneur students on its Edtech platform, GeniusU.The Genius Team AI suite provides entrepreneurs with:32 AI Avatar Expert Advisors based on different perspectives, personalities, and expertise based on famous characters,...

  ● Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year  ● Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and 119% increase year-over-year  ● Q4 and FY Adjusted EBITDA of $1.5 million and $5.4 million; a $6.6 million and 463% increase year-over-year  ● Q4 and FY Cash collections of $10.2 million and $40.4 million; a $9.0 million and 29% increase year-over-year  ● Q4 and FY Volume, Revenue, and Profitability at all-time record levelsPARSIPPANY, NJ, March 07, 2024 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fourth quarter and full year ending December 31, 2023. For the fourth quarter, Interpace reported revenue of $10.3 million and...

Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in vivoKNOXVILLE, TN, March 07, 2024 (GLOBE NEWSWIRE) — Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research on PV-10 (rose bengal sodium) for the treatments of human papillomavirus (“HPV”)-positive and HPV-negative head and neck squamous cell carcinoma (“HNSCC”) will be presented at the upcoming annual meeting of the American Association for Cancer Research (“AACR”), to be held April 5-10, 2024 in San Diego, California. The abstract, which was accepted for a poster presentation, is titled “PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor...